EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Bone quality in LAMA2-related muscular dystrophy and SELENON-related congenital myopathy, a one-year prospective natural history study

Karlijn Bouman, Anne T M Dittrich, Jan T Groothuis, Baziel G M van Engelen, Heidi Zweers-van Essen, Anja de Baaij-Daalmeyer, Mirian C H Janssen, Corrie E Erasmus, Jos M T Draaisma, Nicol C Voermans

Neuromuscular Disorders · 2024

DOI: 10.1016/j.nmd.2023.11.008 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuromuscular Disorders, 2024. Verfasst von Karlijn Bouman und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, the Netherlands; Departme…. Hauptthemen laut MEDLINE: Muscular Diseases, Muscular Dystrophies, Fractures, Bone. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Fragility fractures are frequently reported in neuromuscular diseases and negatively influence functional prognosis, quality of life and survival. In LAMA2-related muscular dystrophy (LAMA2-MD) and SELENON(SEPN1)-related congenital myopathy (SELENON-RM) cross-sectional and prospective natural history studies on bone quality and fragility long bone fractures (LBFs) are lacking. We therefore aim to systematically assess bone quality and provide recommendations for clinical care. We performed a one-year prospective natural history study in 21 LAMA2-MD and 10 SELENON-RM patients including a standardized fracture history and bone quality assessment through dual energy Xray absorptiometry scan (DEXA-scan) and/or bone health index (BHI). Ninety percent of the LAMA2-MD and SELENON-RM patients showed low bone quality. Eight (38%) LAMA2-MD and five (50%) SELENON-RM patients had a history of fragility LBFs. During the one-year follow-up period, one LAMA2-MD patient (female, 3 years) experienced a fragility LBF of the right humerus. We found no difference in bone mineral density between baseline and one-year follow-up. Based on general international guidelines for osteoporosis, we advise adequate vitamin D and calcium intake, and standardized clinical follow-up through a DEXA-scan or BHI in all LAMA2-MD and SELENON-RM patients. On indication, patients should be referred to the pediatrics or internal medicine for consideration of additional treatments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Muscular DiseasesMuscular DystrophiesFractures, BoneHumansChildFemaleCross-Sectional StudiesProspective StudiesQuality of Life

Stichwörter der Autor:innen

Bone mineral densityBone qualityDual energy X-ray absorptiometry scan (DEXA-scan)Fragility long bone fracturesLAMA2-related muscular dystrophySELENON-related congenital myopathy

Autor:innen und Institutionen

  • Department of Neurology, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, the Netherlands; Department of Pediatric Neurology, Donders Institute for Brain, Cognition and…
  • Department of Pediatrics, Radboud Institute for Health Sciences, Amalia Children's Hospital, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Department of Rehabilitation, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Department of Neurology, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Department of Gastroenterology and Hepatology, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Department of Internal Medicine, Radboud University Medical Center, Nijmegen, the Netherlands.

Zitieren

APA

Bouman, K., Dittrich, A. T. M., Groothuis, J. T., van Engelen, B. G. M., Zweers-van Essen, H., de Baaij-Daalmeyer, A., Janssen, M. C. H., Erasmus, C. E., Draaisma, J. M. T., & Voermans, N. C. (2024). Bone quality in LAMA2-related muscular dystrophy and SELENON-related congenital myopathy, a one-year prospective natural history study. Neuromuscular Disorders. https://doi.org/10.1016/j.nmd.2023.11.008

Vancouver

Bouman K, Dittrich ATM, Groothuis JT, van Engelen BGM, Zweers-van Essen H, de Baaij-Daalmeyer A, et al. Bone quality in LAMA2-related muscular dystrophy and SELENON-related congenital myopathy, a one-year prospective natural history study. Neuromuscular Disorders. 2024. doi:10.1016/j.nmd.2023.11.008

BibTeX
@article{Bouman2024,
  author = {Bouman, Karlijn and Dittrich, Anne T M and Groothuis, Jan T and van Engelen, Baziel G M and Zweers-van Essen, Heidi and de Baaij-Daalmeyer, Anja and Janssen, Mirian C H and Erasmus, Corrie E and Draaisma, Jos M T and Voermans, Nicol C},
  title = {Bone quality in LAMA2-related muscular dystrophy and SELENON-related congenital myopathy, a one-year prospective natural history study},
  journal = {Neuromuscular Disorders},
  year = {2024},
  doi = {10.1016/j.nmd.2023.11.008}
}
Kostenlos starten →